Clinical Practice Guidelines Committee


Chair: Dr Andy Lewington,

The Clinical Practice Guidelines Committee was established by the UK Renal Association (RA) to prepare guidelines for the management of patients with renal disease and help identify the data to be collected by the Renal Registry.

The RA has produced guidance on best practice in the management of patients with kidney disease since 1995. The RA Clinical Practice Guidelines are not funded by any external organisation, commercial company or charity.

In 2013 it was agreed that for appropriate topics The Renal Association would produce joint adult and paediatric guidelines with the British Association for Paediatric Nephrology .

NICE Accreditation

The National Institute for Health and Care Excellence (NICE) has accredited the process used by The Renal Association to produce its Clinical Practice Guidelines. Accreditation is valid for 5 years from 9 November 2010.

Accreditation helps health and social care professionals identify the most robustly produced guidance available, enabling them to deliver high quality care.

More information on accreditation can be viewed at


Clinical Practice Guidelines Committee 2016

Dr. Richard Baker
Dr. Vicky Briggs        
Dr. Clara Day   
Dr. Jan Dudley
Dr. Elizabeth Garthwaite                       
Dr. Paul Harden                              
Dr. Suren Kanagasundaram
Dr. Mick Kumwenda
Dr. Andy Lewington (Chair)   
Dr. Elizabeth Lindley    
Dr. Simon Lines
Dr. Mark MacGregor 
Dr. Patrick Mark        
Dr. Shona Methven
Dr. Ashraf Mikhail                           
Dr. Sandip Mitra                 
Dr. Andrew Mooney
Dr. Marlies Ostermann
Dr. Mike Robson
Dr. Ed Sharples
Dr. Simon Steddon  
Ms. Elizabeth Southcott   
Dr.Graham Warwick
Dr. Martin Wilkie                             
Dr. Graham Woodrow
Dr.Mark Wright 

Current Edition of the Clinical Practice Guidelines

Guidelines  Main authors
 Paediatric author  Date review Due 
Acute Kidney Injury  Suren Kanagasundaram, Rajib Pall, Chris Mulgrew, Nikita Agrawal, Marlies Ostermann  David Milford  08/03/11
Anaemia in CKD  Ashraf Mikhail & Sunil Bhandari Jonathan Evans  15/11/10  2015
Assessment of the Potential KidneyTransplant Recipient  Chris Dudley & Paul Harden Jan Dudley  12/01/11  2015
Blood-borne viruses  Colin Geddes, Elizabeth Lindley, Neill Duncan & Elizabeth Garthwaite    14/07/09  2014
Cardiovascular disease in CKD  Stephen Holt & David Goldsmith Rukshana Shroff  06/08/10  2015
CKD-Mineral and Bone Disorders (CKD-MBD)
Simon Steddon & Edward Sharples Rukshana Shroff  01/03/15  2020
Detection, Monitoring and Care of Patients with CKD  Mark MacGregor & Maarten Taal    28/02/11  2015
Haemodialysis  Elizabeth Lindley & Sandy Mitra  Daljit Hothi/Kay Tyermann  01/12/09 2012 
Nutrition in CKD  Mark Wright & Elizabeth Southcott
   25/06/10  2015
Peritoneal access  Martin Wilkie
Carol Inward  22/09/09 2014 
Peritoneal dialysis  Graham Woodrow & Stanley Fan Chris Reid  30/07/10 2015 
Planning, initiation & withdrawal of Renal Replacement Therapy   Graham Warwick & Andrew Mooney    01/01/14 2019 
Post-operative Care of the Kidney Transplant Recipient   Kate Stevens, Paddy Marks,
Rajan Patel & Richard Baker 
Heather Maxwell  05/02/11  2015
Vascular Access For Haemodialysis R Baker, A Jardine & Peter Andrews    31/3/15  2020


Recent Activity

Tolvaptan for treating autosomal dominant polycystic kidney disease

In October 2015, NICE recommended that Tolvaptan (JINARC®) therapy should be made available for selected patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in England and Wales In January 2016, the Scottish Medicines Consortium (SMC) also approved Tolvaptan for use in Scotland. Currently Tolvaptan is being used in Canada, Japan, Korea and Switzerland for ADPKD and has been approved for use in Europe by the European Medicines Agency (EMA). 

NICE recommended that patients with ADPKD who may be eligible for treatment must have Stage 2 or 3 chronic kidney disease (CKD) and ‘evidence of rapidly progressing disease’. SMC have approved its use for Stages 1-3 CKD, similar to that recommended by the EMA. The definition and evaluation of ‘rapid progression’ are however not established and have not been stipulated by NICE, SMC or the EMA.  The main purpose of this commentary is to address the issue of how to identify patients with evidence of or who are at risk of rapid disease progression.

The draft guideline will is available to you for consultation and feedback over the next 3 months; please send your  comments  to Professor Ong at

Please click here to view the draft guideline

New RA and ART Guideline on Water Treatment Facilities, Dialysis Water and Dialysis Fluid Quality for Haemodialysis and Related Therapies 

Please click here to view the joint guideline. 



© Renal Association 2013
All rights reserved. Use of this website constitutes acceptance of the Privacy Policy and Terms and Conditions.

Design and Development  by MCI
Contact us
The Renal Association
Durford Mill
GU31 5AZ
Tel: 01730 715 215
Fax: 01730 715 291